Which Biopharmaceutical Companies Are Big Spenders?
This week’s BioBlog is stocked full of interesting articles on Big Data in Cancer, NCNC Appropriate Use Criteria, the Voice of the Patient, CMS Eases MACRA Timeline, and much more.
This article from GEN explains, “With the potential for billions in new revenues, biopharma giants have proven willing to shell out billions in collaborations with smaller biotechs aimed at developing new immunotherapies for cancer”.
Learn about the results of a study in which both the patients and oncologists received specialized communication training.
In this article, we look at positive findings associated with many investigational therapies, including therapies for the treatment of patients with B-cell malignancies or acute myeloid leukemia (AML); a vaccine for the treatment of patients with AML; and a chimeric monoclonal antibody a for the treatment of patients with advanced gastric cancers.
NCCN Imaging Appropriate Use Criteria to be Integrated into New Century Health’s Oncology Clinical Decision Support Platform
“We strongly believe that expanding our strategic collaboration with NCCN strengthens our ability to bring enhanced clinical value to oncologists,” said Atul Dhir, MD, DPhil, Chief Executive Officer, New Century Health.
Acting CMS Administrator Andy Slavitt lays out four pathways to compliance with the new Quality Payment Program (in order of easiest to the hardest).
“We looked more broadly at drug molecule features that drug developers thought were unimportant in predicting drug safety in the past. Then we let the data speak for itself,” said author Dr. Olivier Elemento.
Understanding the costs of care may be particularly relevant for patients who can choose among several guideline-concordant adjuvant chemotherapy regimens of similar efficacy, suggested Sharon H. Giordano, MD, MPH, Department Chair, Department of Health Services Research, M.D. Anderson Cancer Center, Houston, TX.